N-(tert-butoxycarbonyl)-D-3-deoxymimosine | 160282-85-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(tert-butoxycarbonyl)-D-3-deoxymimosine
• CAS: 160282-85-9
• 化学式: C₁₃H₁₈N₂O₅
• 分子量: 282.296
• InChiKey: GPQJTCBFOAVYOT-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.83
• 重原子数：
  20.0
• 可旋转键数：
  4.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  97.63
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  N-(tert-butoxycarbonyl)-D-3-deoxymimosine 在 N-甲基吗啉 作用下， 以 水 、 N,N-二甲基甲酰胺 、 叔丁醇 为溶剂， 反应 21.67h， 生成
  参考文献：
  名称：

  Synthesis of [L-3-Deoxymimosine4]-angiotensin I as an approach to the preparation of selective protein-tyrosine kinase (PTK) inhibitors

  摘要：

  tert-Boc-L-3-Deoxymimosine (13) and tert-Boc-D-Deoxymimosine (16) were prepared in two steps from tert-Boc-L-asparagine and tert-Boc-D-asparagine, respectively. Both 13 and id were determined to be optically pure by derivatization with Marphey's reagent. Activation and coupling of 16 to L-isoleucine methyl ester resulted in a diastereomeric mixture of products containing 96% of the DL diastereomer and 4% of the LL diastereomer. [L-3-Deoxymimosine(4)]-angiotensin I war synthesized from 13 as an approach to the design and synthesis of selective protein-tyrosine kinase (PTK) inhibitors.

  DOI：

  10.1016/s0040-4020(01)89603-4
• 作为产物：
  描述：

  Boc-D-天冬酰胺 在 吡啶 、 [双(三氟乙酰氧基)碘]苯 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 N-(tert-butoxycarbonyl)-D-3-deoxymimosine
  参考文献：
  名称：

  Synthesis of [L-3-Deoxymimosine4]-angiotensin I as an approach to the preparation of selective protein-tyrosine kinase (PTK) inhibitors

  摘要：

  tert-Boc-L-3-Deoxymimosine (13) and tert-Boc-D-Deoxymimosine (16) were prepared in two steps from tert-Boc-L-asparagine and tert-Boc-D-asparagine, respectively. Both 13 and id were determined to be optically pure by derivatization with Marphey's reagent. Activation and coupling of 16 to L-isoleucine methyl ester resulted in a diastereomeric mixture of products containing 96% of the DL diastereomer and 4% of the LL diastereomer. [L-3-Deoxymimosine(4)]-angiotensin I war synthesized from 13 as an approach to the design and synthesis of selective protein-tyrosine kinase (PTK) inhibitors.

  DOI：

  10.1016/s0040-4020(01)89603-4